Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2010

View Archived Issues

Prucalopride is safe and efficacious in opioid-induced constipation

Amantadine and fluoxetine display comparable efficacy in major depressive disorder

Technetium-99m-labeled MIP-1340 shows suitability for prostate cancer imaging

Banyu Pharmaceutical discloses new DGAT-1 inhibitors

OriBase Pharma describes new tyrosine protein kinase inhibitors

Italian scientists synthesize new HDAC inhibitor

Ivabradine improves outcome of patients with heart failure in SHIFT trial

BioFocus and Usher III Initiative partner to discover drugs for Usher's syndrome type III

AstraZeneca identifies new histamine H3 receptor antagonists

CytRx begins phase II bafetinib trial in advanced prostate cancer

Shionogi claims new P2X3 and P2X2/3 receptor antagonists

Rexahn submits protocol to FDA for phase IIb RX-10100 trial

Arrow Therapeutics discloses new antivirals for HCV infection

La Jolla Pharma seeks candidate small-molecule therapeutics to inlicense or acquire

Promedior begins phase IIa trial of PRM-151 for postsurgical scarring in glaucoma

Somaxon launches Silenor in U.S. for insomnia

FDA clears IND for Tekmira's TKM-PLK1

Enrollment reinitiated in phase III trial of zanolimumab in CTCL

Merz Pharma Canada's Xeomin to be listed with regular benefit status

Idenix's IDX-184 and IDX-320 programs in HCV infection on clinical hold

Phase III REALIZE trial of telaprevir in HCV infection meets primary endpoint

Onyx and Ono sign Japanese agreements for oncology drugs carfilzomib and ONX-0912

Thomson Reuters salutes winner of 2010 IUPAC-Richter Prize in Medicinal Chemistry

Can-Fite files IND application for phase III CF-101 trial in dry eye syndrome

Abbott acquires Piramal's Healthcare Solutions business

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 25, 2025.
Moderna expands mRNA tech to latent viruses, cancer, rare disease
BioWorld
Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
Revmed goes global with $2B in capital for RAS(ON) inhibitors
BioWorld
Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...
No vote, ACIP recurring theme at CDC confirmation hearing
BioWorld
Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric...